Kourosh Ravvaz1, John A Weissert1, Arshad Jahangir2, Christian T Ruff3. 1. Advocate Aurora Research Institute, Advocate Aurora Health, Milwaukee, Wisconsin, United States of America. 2. Center for Advanced Atrial Fibrillation Therapies, Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Milwaukee, Wisconsin, United States of America. 3. TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Abstract
BACKGROUND: The risk of thromboembolism and bleeding before initiation of oral anticoagulant (OAC) in atrial fibrillation patients is estimated by CHA2DS2-VASc and HAS-BLED scoring system, respectively. Patients' socioeconomic status (SES) could influence these risks, but its impact on the two risk scores' predictive performance with respect to clinical events remains unknown. Our objective was to determine if patient SES defined by area deprivation index (ADI), in conjunction with CHA2DS2-VASc and HAS-BLED scores, could guide oral anticoagulation therapy. METHODS AND FINDINGS: The study cohort included newly diagnosed patients with AF who were treated with warfarin. The cohort was stratified by the time in therapeutic range of INR (TTR), ADI, CHA2DS2-VASc, and HAS-BLED risk scores. TTR and ischemic and bleeding events during the first year of therapy were compared across subpopulations. Among 7274 patients, those living in the two most deprived quintiles (ADI ≥60%) had a significantly higher risk of ischemic events and those in the most deprived quintile (ADI≥80%) had a significantly increased risk of bleeding events. ADI significantly improved the predictive performance of CHA2DS2-VASc but not HAS-BLED risk scores. CONCLUSION: ADI can predict increased risk for ischemic and bleeding events in the first year of warfarin therapy in patients with incident AF.
BACKGROUND: The risk of thromboembolism and bleeding before initiation of oral anticoagulant (OAC) in atrial fibrillationpatients is estimated by CHA2DS2-VASc and HAS-BLED scoring system, respectively. Patients' socioeconomic status (SES) could influence these risks, but its impact on the two risk scores' predictive performance with respect to clinical events remains unknown. Our objective was to determine if patient SES defined by area deprivation index (ADI), in conjunction with CHA2DS2-VASc and HAS-BLED scores, could guide oral anticoagulation therapy. METHODS AND FINDINGS: The study cohort included newly diagnosed patients with AF who were treated with warfarin. The cohort was stratified by the time in therapeutic range of INR (TTR), ADI, CHA2DS2-VASc, and HAS-BLED risk scores. TTR and ischemic and bleeding events during the first year of therapy were compared across subpopulations. Among 7274 patients, those living in the two most deprived quintiles (ADI ≥60%) had a significantly higher risk of ischemic events and those in the most deprived quintile (ADI≥80%) had a significantly increased risk of bleeding events. ADI significantly improved the predictive performance of CHA2DS2-VASc but not HAS-BLED risk scores. CONCLUSION: ADI can predict increased risk for ischemic and bleeding events in the first year of warfarin therapy in patients with incident AF.
Authors: Dariush Mozaffarian; Emelia J Benjamin; Alan S Go; Donna K Arnett; Michael J Blaha; Mary Cushman; Sarah de Ferranti; Jean-Pierre Després; Heather J Fullerton; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Simin Liu; Rachel H Mackey; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Paul Muntner; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Graham Nichol; Latha Palaniappan; Dilip K Pandey; Mathew J Reeves; Carlos J Rodriguez; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Joshua Z Willey; Daniel Woo; Robert W Yeh; Melanie B Turner Journal: Circulation Date: 2014-12-17 Impact factor: 29.690
Authors: Jared D Miller; Konstantinos N Aronis; Jonathan Chrispin; Kaustubha D Patil; Joseph E Marine; Seth S Martin; Michael J Blaha; Roger S Blumenthal; Hugh Calkins Journal: J Am Coll Cardiol Date: 2015-12-29 Impact factor: 24.094
Authors: Samuli Jaakkola; Tuomas O Kiviniemi; Ilpo Nuotio; Juha Hartikainen; Pirjo Mustonen; Antti Palomäki; Jussi Jaakkola; Antti Ylitalo; Päivi Hartikainen; K E Juhani Airaksinen Journal: Am J Cardiol Date: 2018-02-12 Impact factor: 2.778
Authors: Amy J H Kind; Steve Jencks; Jane Brock; Menggang Yu; Christie Bartels; William Ehlenbach; Caprice Greenberg; Maureen Smith Journal: Ann Intern Med Date: 2014-12-02 Impact factor: 25.391
Authors: Konsta Teppo; Jussi Jaakkola; Fausto Biancari; Olli Halminen; Miika Linna; Jari Haukka; Jukka Putaala; Pirjo Mustonen; Janne Kinnunen; Alex Luojus; Saga Itäinen-Strömberg; Juha Hartikainen; Aapo L Aro; K E Juhani Airaksinen; Mika Lehto Journal: Int J Cardiol Heart Vasc Date: 2022-06-13
Authors: Konsta Teppo; Jussi Jaakkola; Fausto Biancari; Olli Halminen; Miika Linna; Jari Haukka; Jukka Putaala; Paula Tiili; Ossi Lehtonen; Mikko Niemi; Pirjo Mustonen; Janne Kinnunen; Juha Hartikainen; K E Juhani Airaksinen; Mika Lehto Journal: Pharmacol Res Perspect Date: 2022-06
Authors: Fausto Biancari; Konsta Teppo; Jussi Jaakkola; Olli Halminen; Miika Linna; Jari Haukka; Jukka Putaala; Pirjo Mustonen; Janne Kinnunen; Juha Hartikainen; Aapo Aro; Juhani Airaksinen; Mika Lehto Journal: J Epidemiol Community Health Date: 2022-06-15 Impact factor: 6.286
Authors: Konsta Teppo; Jussi Jaakkola; Fausto Biancari; Olli Halminen; Miika Linna; Jukka Putaala; Pirjo Mustonen; Janne Kinnunen; Santeri Jolkkonen; Mikko Niemi; Juha Hartikainen; K E Juhani Airaksinen; Mika Lehto Journal: Int J Cardiol Heart Vasc Date: 2022-10-10